Introduction {#S1}
============

The Hippo pathway, originally identified in the *Drosophila* genus, is a highly conserved kinase cascade that regulates organ size ([@B31]; [@B91]; [@B34]). The transcriptional coactivator Yes-associated protein 1 (YAP1; homolog of Yorkie) was first identified as a binding partner of the SH3 domain of c-yes; the YAP1 and its paralog PDZ-binding motif (TAZ; also known as WW--domain-containing transcription regulator 1 \[WWTR1\]), are both downstream effectors of Hippo signaling ([@B105]). This pathway has been implicated in diverse biological functions, both in *Drosophila* and in mammals; these include cell proliferation, apoptosis, organ-size control, and cancer progression ([@B79]). Recent reports have revealed the critical role of YAP1/TAZ in cardiac development, regeneration, and stress response; however, there are some inconsistent and even contradictory results that warrant further investigation ([@B136]). Interestingly, recent studies have identified a variety of post-translational modifications (PTMs) to YAP1/TAZ, such as phosphorylation, O-GlcNacylation, methylation, and ubiquitination, which offers an opportunity to control the Hippo--YAP1/TAZ pathway. In this review, we summarize the overall picture of the Hippo--YAP1/TAZ pathway; in particular, we highlight the novel discoveries with regard to PTM-related regulation and the function of the YAP1/TAZ pathway in cardiac development, disease and regeneration.

Overview of the Hippo--YAP1/TAZ Pathway {#S2}
=======================================

The Canonical Hippo--YAP1/TAZ Pathway in Mammals {#S2.SS1}
------------------------------------------------

The components of the Hippo pathway in mammals are highly consistent with those in *Drosophila*, including sterile 20-like protein kinases (MST1/2; homologs of D. Hpo), salvador family protein 1 (SAV1; which contains a WW domain), large tumor suppressors (LATS1/2; homologs of Wts), Mps one binder kinase activator-like 1A/1B (MOB1; orthologs of Mats), YAP1/TAZ, and other peripheral proteins ([Figure 1](#F1){ref-type="fig"}).

![The Hippo--YAP1/TAZ pathway in cardiac biology. Both YAP1 and TAZ are phosphorylated by core components, including Mst1/2, SAV1, Lats1/2, and MOB1, of the canonical Hippo pathway, and are subsequently degraded or stranded in the cytoplasm. Active YAP1/TAZ translocate to the nucleus, bind to transcriptional partners, and modulate downstream output in cardiac tissue. In addition, the Hippo-YAP1/TAZ pathway is regulated by several upstream pathways and cell-cell junctions. Line arrows indicate activation, whereas connector lines imply inhibition.](fphys-11-00389-g001){#F1}

The upstream signals and stressors of the Hippo pathway include cell polarity, energy stresses, G--protein-coupled receptors (GPCRs), and stiffness of the extracellular matrix (ECM) ([@B77]). On stimulation, MST1/2 and its adaptor protein SAV1 are phosphorylated leading to their activation; subsequently, these stimulate the phosphorylation, and activation of the LATS1/2--MOB1 complex. Through an interaction between the PPxY (PY) motifs of LATS1/2 and the WW domains of YAP1/TAZ, the activated LATS1/2 can induce phosphorylation of YAP1 (mouse YAP1 at Ser112, human YAP1 at Ser127) and TAZ (Ser89) ([@B133]). After phosphorylation, YAP1/TAZ binds to the 14-3-3 protein, which induces cytoplasmic retention of YAP1/TAZ. Moreover, phosphorylated YAP1/TAZ is likely to undergo ubiquitination degradation that is dependent on the β-transducin repeat-containing E3 ubiquitin protein ligase complex (SCF^β--TRCP^) ([@B20]; [@B133]).

When Hippo signaling is inactive, the YAP1/TAZ are activated and mainly localized in the nucleus, where they produce downstream biological effects. The YAP1/TAZ do not harbor DNA-binding domains; instead, these interact with transcriptional partner proteins to initiate or impede transcription. The transcriptional partners of YAP1/TAZ that have been identified thus far include transcriptional enhanced associate domain proteins (TEADs), members of the Smad family ([@B2]; [@B8]; [@B78]; [@B97]), and p63/p73 ([@B59]; [@B51]). The onus of the YAP1/TAZ biological output rests with the transcriptional partners and the target genes that they modulate.

Downstream Output of YAP1/TAZ {#S2.SS2}
-----------------------------

As orthologs of *Drosophila* Scalloped, the TEAD family of proteins in mammals comprise YAP1/TAZ- and DNA-binding domains, which facilitates the construction of a YAP1/TAZ--TEADs co-transcription complex ([@B63]). Recent studies investigating YAP1/TAZ mechanisms have identified some target genes of the YAP1/TAZ--TEADs complex. The *glucose transporter 1* (*Glut1*) promotor contains TEAD-binding motifs that allow *Glut1* to be regulated by the YAP1--TEAD1 transcriptional complex, which enhances cell glycolysis in breast cancer cells ([@B114]; [@B65]). Moreover, GLUT1, a transmembranous protein, participates in cell glucose uptake ([@B117]). Left ventricular hypertrophy is characterized by enhanced GLUT1 expression and basal glucose uptake in heart tissues. Cardiac-specific overexpression of GLUT1 can retard the progression of heart failure and reduce mortality associated with pressure overload (PO) ([@B64]). Thus, YAP1/TAZ may have a cardioprotective effect by enhancing GLUT1 expression. In breast cancer cells, the *G2 and S phase-expressed 1* (*GTSE1*) acts as a novel target gene of the YAP1--TEAD4 complex, which forms cell protrusions and boosts cell migration ([@B104]). The GTSE1 is a microtubule-associated protein that is involved in cell proliferation, invasion, and migration ([@B68]). Therefore, through regulation of GTSE1, YAP1 facilitates epithelial-to-mesenchymal transition (EMT) in cancer cells.

Furthermore, the YAP1/TAZ--TEAD complex can recruit and bind to transcription enhancers and/or mediators to potentiate and blunt transcription. Prox1, a major regulator of lymphangiogenesis, is regulated by the YAP1/TAZ--TEAD complex ([@B32]; [@B14]). The YAP1/TAZ--TEAD transcriptional complex recruits the nucleosome remodeling and histone deacetylase (NuRD) complex to negatively modulate *Prox1*; this was shown to reduce pathological lymphangiogenesis and maintain the lymphatic valve postnatally ([@B14]). In addition, the YAP1/TAZ, together with histone deacetylase 7 (HDAC7) and TEAD, binds to the *COX-2* promoter and attenuates *COX-2* transcription in order to inhibit IL-1β-induced cell migration and invasion ([@B128]). Based on its tyrosine phosphorylation status, parafibromin (a nuclear scaffold protein) selectively interacts with YAP1 or TAZ. Phosphorylated parafibromin binds to the YAP1-TEAD complex, whereas dephosphorylated parafibromin combines with the TAZ-TEAD transcriptional activator ([@B108]). YAP1 and TAZ have largely overlapping transcriptional functions, such as cell proliferation and cell migration; however, both have unique biological functions ([@B55]; [@B70]; [@B87]). For example, YAP1 knockout (KO), rather than TAZ KO, in mice leads to embryonic death ([@B39]; [@B74]). Conversely, parafibromin regulates the activity of YAP1 and TAZ in different status, which may explain the unique functions of YAP1 and TAZ.

Newly discovered co-transcription proteins reportedly contribute to YAP1/TAZ functions. Pyruvate kinase M2 (PKM2) is a relevant glycolytic protein; the interaction of YAP1 with hypoxia-inducible factor 1α (HIF-1α) promotes tumor cell glycolysis by triggering the transcription of the *Pkm2* gene ([@B130]). YAP1-mediated PKM2 expression enhances cell glycolysis and adapts tumor cells for abnormal growth. The SWI/SNF (Brg/Brahma-associated factors \[BAF\]) and ARID1A (BAF250A) proteins are inhibitors of the YAP1/TAZ-TEADs complex; in addition, these are capable of occupying the TEAD-binding site of YAP1/TAZ ([@B13]). Although the ARID1A--SWI/SNF complex is inactive during tumor growth, this negative association highlights the role of the ARID1A--SWI/SNF complex in cancer development through the suppression of oncogenic YAP1/TAZ activity ([@B46]).

Collectively, novel transcription mechanisms have been reported for explaining partly YAP1/TAZ biological output; these findings bode well for future YAP1/TAZ studies. However, the diversity of transcription partners and the target genes of YAP1/TAZ make it difficult to clarify the biological effects of YAP1/TAZ; therefore, future research should consider the entire molecular network of the YAP1/TAZ pathway.

Regulation of the YAP1/TAZ by Post-Translational Modifications {#S3}
==============================================================

Regulation of the YAP1/TAZ by Phosphorylation {#S3.SS1}
---------------------------------------------

Yes-associated protein 1 and TAZ, two salient downstream effectors of Hippo signaling, are found both in the cytoplasm and nucleus. Since these two effectors trigger target gene transcription in the nucleus, nuclear accumulation of YAP1/TAZ is a key step in their mechanism of action. This nuclear accumulation is mediated by several events: (1) post-translational modifications (PTMs) including phosphorylation, methylation, and ubiquitination; (2) other related protein interactions with YAP1/TAZ; and (3) translational interference ([@B95]; [@B79]). In most scenarios, YAP1/TAZ are mediated by PTMs that determine their subcellular localization and content ([Table 1](#T1){ref-type="table"}).

###### 

Post-translational modifications that modulate YAP1/TAZ.

  Modification types   Regulative sites                   Enzymes        Effects
  -------------------- ---------------------------------- -------------- -------------------------------------------------------------------------------------------------
  Phosphorylation      Ser109                             LATS1/2        YAP1/TAZ cytoplasm retention ([@B132])
                       Ser127 (Ser89 in TAZ)              LATS1/2        Binding YAP1 to 14-3-3 and inducing cytoplasm retention ([@B133])
                       Ser128                             NLK            Blocking YAP1 binding to 14-3-3 ([@B81])
                       Ser381 (Ser311 in TAZ)             LATS1/2        β--Trcp-dependent ubiquitination degradation ([@B132])
                       NS                                 PRP4K          YAP1/TAZ nuclear export ([@B15])
                       Tyr357                             c-Abl          Stabilizing YAP1 stable and increasing YAP1--p73 interaction inducing cell apoptosis ([@B59])
                       Tyr357                             Src            Enhancing YAP1 nuclear retention and target gene *CTGF* expression ([@B110])
                       one or more tyrosine residues      Yes            Promoting YAP1 translocation and *Oct-3/4* transcription ([@B107])
  Dephosphorylation    Ser127 (Ser89 and Ser311 in TAZ)   PP1A           YAP1/TAZ nuclear translocation ([@B69]; [@B118]).
  O-GlcNacylation      Ser109                             OGT            Impeding LATS1/2-induced YAP1 Ser109 phosphorylation and potentiating YAP1 activity ([@B93])
                       Thr241                             OGT            Attenuating LATS1/2-dependent YAP1 Ser127 phosphorylation and enhancing YAP1 activity ([@B131])
  Methylation          Lys342                             SET1A          Dampening YAP1--CRM1 fusion and enhancing YAP1 nuclear retention ([@B25])
                       Lys494                             SET7           Enhancing YAP1 translocation to cytosol and cytoplasmic membrane [@B90])
  Ubiquitination       NS                                 SCF^β--TRCP^   YAP1/TAZ protein degradation ([@B20]; [@B133])
                       NS                                 Fbxw7          YAP1 protein degradation ([@B113]; [@B129])
                       Lys321, Lys497                     SKP2           Accumulating YAP1 nuclear localization and association between YAP1 and TEAD ([@B127])
  De-ubiquitination    NS                                 USP9X          Stabilizing YAP1 and enhancing its activity ([@B61]).
                       NS                                 OTUD1          Reducing YAP1 stability and attenuating the cell proliferation activity of YAP1 ([@B127]).

NS, not specified, where the specific regulator sites have not been validated.

In the canonical Hippo pathway, phosphorylation plays a pivotal role in the regulation of YAP1/TAZ; they can be phosphorylated at multiple sites, such as Ser61, Ser109, Ser127 (Ser89 in TAZ), Ser164, and Ser381 (Ser311 in TAZ) ([@B132]). Among these, Ser127 and Ser381 are the main phosphorylation sites by LATS1/2. Following phosphorylation at Ser381, YAP1 is prone to further phosphorylation by the casein kinase I isoform δ/ε (CKI δ/ε), which eventually promotes SCF^β--TRCP^-induced ubiquitination degradation of YAP1 ([@B132]). YAP1 binds to 14-3-3 protein through the Ser127 phosphorylation-dependent way and becomes sequestered in the cytoplasm ([@B133]). Notably, the combination of YAP1 and 14-3-3 can be blocked by phosphorylation at the YAP1 Ser128 site by Nemo-like kinase (NLK); this phenomenon can also be seen in *Drosophila* Nemo ([@B81]). This indicates that NLK/Nemo are highly conserved in Hippo-YAP1/TAZ signaling to mediate the YAP1/Yki subcellular compartmentation via phosphorylation.

Phosphorylation-dependent cytoplasmic retention of YAP1/TAZ may hamper their transcriptional activity. In the transgenic heart, MST1 overexpression was shown to enhance the phosphorylation of YAP1 Ser127 and induce inactivation of YAP1; this induced cardiomyocyte (CM) apoptosis and myocardial fibrosis ([@B125]; [@B135]). In LATS1/2 cardiac knock out (CKO) of the embryonic epicardium, LAST1/2 deficiency was shown to inhibit the phosphorylation of YAP1 Ser127 and increase the YAP1 transcriptional activity; eventually, this resulted in the failure of subepicardial cells to differentiate into cardiac fibroblasts and induced coronary vessel defects ([@B121]). Thus, the canonical Hippo pathway inhibits the YAP1/TAZ activity in cardiac tissues through phosphorylation. Interestingly, YAP1/TAZ was shown to increase the concentration and activity of endogenous LATS2 by directly inducing TEAD-dependent *LATS2* transcription and/or indirectly activating neurofibromin 2 (NF2)-mediated LATS2 activity, which subsequently enhances the phosphorylation of YAP1/TAZ ([@B83]; [@B16]). This physiological negative feedback mechanism is expected to maintain the dynamic homeostasis of the Hippo pathway, and may help elucidate the complex mechanism of cardiac development and disease.

Notably, YAP1/TAZ can be dephosphorylated by a catalytic subunit of protein phosphatase-1 (PP1A) at Ser127 (Ser89 and Ser311 in TAZ), and is then translocated into the nucleus, thereby causing leak activation of the target gene ([@B69]; [@B118]). This abnormal activation can be potentially prevented by some mechanisms. The pre-mRNA splicing factor 4 kinase (PRP4K) promotes phosphorylation of Yki/YAP1/TAZ in the nucleus as well as its subsequent nuclear export; this acts as a safety threshold for the rescue of aberrant Yki/YAP1/TAZ activities and cell growth ([@B15]).

Besides serine phosphorylation, the subcellular distribution and activities of YAP1/TAZ are affected by the phosphorylation of tyrosine residues. Several members of the SRC family of kinases (SFK), such as Yes, Src, and c-Abl, participate in tyrosine phosphorylation of YAP1. In response to DNA damage, YAP1 Tyr357 phosphorylation by c-Abl stabilizes YAP1 and increases the nuclear interaction of YAP1-p73 to induce apoptosis ([@B59]). This phosphorylation may inhibit the cell proliferation and oncogenic ability of YAP1 that are necessary to sustain its normal biological functions. The activated Yes phosphorylates YAP1 on one or more tyrosine residues; the phosphorylated YAP1 is subsequently translocated to the nucleus to trigger the transcription of the pluripotency factor *Oct-3/4*, which is critical for maintaining the self-renewal ability of the mouse and human embryonic stem cells (hESCs) ([@B107]). Furthermore, Src phosphorylated by the IL6--GP130 complex phosphorylates YAP1 at Tyr357, which increases YAP1 nuclear retention and expression of its target gene *connective tissue growth factor* (*CTGF*); this Src-induced YAP phosphorylation facilitates the regeneration of the injured intestinal mucosa ([@B110]). The above-mentioned research shows that tyrosine phosphorylation participates in the regulation of YAP1/TAZ in specific cell and tissue regeneration. This suggests that the tyrosine phosphorylation of YAP1/TAZ may be conductive to embryonic cardiac development and post-injury cardiac regeneration; these findings provide new insights into cardiac development and regeneration.

Regulation of the YAP1/TAZ by O-GlcNAcylation {#S3.SS2}
---------------------------------------------

Besides phosphorylation, several PTMs, such as O-GlcNAcylation, are involved in the regulation of YAP1/TAZ. O-GlcNAc transferase (OGT) directly induces O-GlcNAcylation at YAP1 Ser109 and Thr241, and potentiates the pro-proliferation activity of YAP1 in pancreatic cancer and liver cancer cells ([@B93]; [@B131]). Mechanistically, YAP1 O-GlcNAcylation can affect YAP1 phosphorylation. As mentioned in Section "Regulation of the YAP1/TAZ by Phosphorylation," LATS1/2 can phosphorylate YAP1 Ser109 ([@B132]). Therefore, O-GlcNAcylation and phosphorylation may act competitively at Ser109. The stoichiometry of Ser109 phosphorylation is much lower than that of O-GlcNAcylation, which suggests that O-GlcNAcylation plays a key role in PTM at this site rather than phosphorylation ([@B93]). O-GlcNAcylation at YAP1 Thr241 can attenuate the phosphorylation of YAP1 at Ser127 via interrupting the LATS1/2 interaction ([@B131]). In addition, these studies reveal that YAP1 not only acts as a substrate of OGT but also triggers *OGT* transcription to regulate its expression, thereby forming a positive feedback loop ([@B93]; [@B131]). This positive feedback loop further regulates YAP1 activity and output.

Therefore, YAP1 may participate in cancer glycosylation metabolism through O-GlcNAcylation and OGT expression in order to maintain the abnormal proliferation and survival of cancer cells. *In vitro*, OGT KO inhibits O-GlcNAcylation at the YAP1 Ser109, thereby inhibiting cell-colony formation in pancreatic cancer; *in vivo*, OGT knockdown downregulates tumor growth ([@B93]). High glucose stimulation improves the level of O-GlcNAcylation at YAP1 Thr241; in addition, O-GlcNAcylation enhances the stability and activity of YAP1, which subsequently induces cell proliferation and transformative phenotypes in hepatocellular carcinoma cells (HCC, THLE-3, and HL-7702 cell lines) ([@B131]). In addition to liver cancer, high glucose level affects diabetic cardiomyopathy. Elevated cardiac concentrations of active YAP1 have been demonstrated in mice fed with high-fat diet and in patients with diabetic cardiomyopathy ([@B44]). However, the relationship between YAP1 and diabetic cardiomyopathy is not completely clear. Thus, YAP1 O-GlcNAcylation might be a promising target for the study of diabetic cardiomyopathy.

Regulation of the YAP1/TAZ by Ubiquitination {#S3.SS3}
--------------------------------------------

The stability and content of YAP1/TAZ are partly regulated by ubiquitination-induced degradation; therefore, ubiquitination cannot be neglected in research into YAP1/TAZ. SCF^β--TRCP^-dependent ubiquitination is a well-known YAP1/TAZ degradation mechanism in the canonical Hippo pathway that is dependent on YAP1/TAZ phosphorylation ([@B20]; [@B133]). Similarly, Fbxw7, another subunit of E3 ligase, participates in the regulation of YAP1 protein level and activity via ubiquitination and proteasomal degradation ([@B113]; [@B129]). Fbxw7 expression exhibits a negative correlation with YAP1 content in human HCC and pancreatic ductal adenocarcinoma tissues; however, the regulatory mechanisms are yet to be elucidated. This proteolytic ubiquitination can be reversed by deubiquitinases; the deubiquitinase USP9X was shown to directly deubiquitinate and stabilize YAP1, leading to enhanced YAP1 activity and promotion of tumor growth ([@B61]). LATS1/2, activated by mono-ubiquitinated angiomotin-like 2 (AMOTL2), triggers YAP1 phosphorylation and suppresses its activity ([@B50]). USP9X deubiquitinates AMOTL2 to inactivate LATS1/2, which indirectly activates YAP1 ([@B50]). Therefore, ubiquitination appears to be a negative regulatory factor for YAP1/TAZ in the canonical Hippo pathway.

Intriguingly, recent studies have provided new insights into ubiquitination independent of the Hippo pathway. The SCF^SKP2^ E3 ligase complex (SKP2) facilitates K63-linkage-specific ubiquitination of YAP1 at Lys321 and Lys497, which does not reduce YAP1 abundance ([@B127]). Moreover, these ubiquitination promotes nuclear translocation of YAP1, and cements the association between YAP1 and TEAD to enhance the cell proliferation activity of YAP1 ([@B127]). This non-proteolytic ubiquitination can be reversed by the binding and interaction between deubiquitinase OTUD1 and YAP1; OTUD1 decreases YAP1 stability, and attenuates the cell proliferation and tumor-growth activity of YAP1 ([@B127]). Obviously, this non-proteolytic ubiquitination is beneficial for YAP1 activation and output. The above-mentioned studies delineate the controversial role of ubiquitination in YAP1/TAZ in the canonical Hippo--YAP1/TAZ pathway as well as in the Hippo-independent pathway. YAP1/TAZ is degraded by ubiquitinases that exert proteolytic effects, whereas it is stabilized by ubiquitinases with non-proteolytic activities; these events can be reversed by the related deubiquitinases. Undoubtedly, ubiquitination plays an essential role in mediating YAP1/TAZ content and stability that should be further studied. The biological effects of ubiquitinated/deubiquitinated YAP1/TAZ have been investigated mainly in tumorigenesis, and less so in cardiogenesis and cardiac disease.

Regulation of the YAP1/TAZ by Methylation {#S3.SS4}
-----------------------------------------

Chromosomal maintenance 1 (CRM1), a nuclear export protein, triggers the nuclear export of YAP1. The methyltransferase SET1A targets YAP1 at Lys342 through mono-methylation, which inhibits CRM1-induced nuclear export of YAP1 with resultant enhancement of YAP1 nuclear retention and transcriptional activity ([@B25]). Mono-methylation at Lys342 in YAP1 contributes to *in vivo* cell proliferation and tumorigenesis ([@B25]). However, this result was discordant with that from a previous study on mono-methylated YAP1. The SET7 is a methyltransferase that connects the cell membrane and the cytoskeleton ([@B27]). Mono-methylation of YAP1 Lys494 by SET7 is necessary for the retention of YAP1 in the cytosol and at the cytoplasmic membrane, which may impede interactions between YAP1 and PDZ-dependent-binding partners ([@B90]). Thus, methylation at YAP1 Lys494 represses YAP1 activity to downregulate *CTGF* transcription. Evidently, methylation can exert certain effects on YAP1/TAZ, but there is a paucity of studies on YAP1/TAZ methylation and their biological output. In addition, the mechanisms by which methylated YAP1/TAZ affect cardiac biology remain unknown.

Several types of PTMs alter the subcellular translocation of YAP1/TAZ to regulate their activities and output, regardless of how YAP1/TAZ are modified by PTMs. Therefore, it is important to study the nuclear--cytoplasmic trafficking of YAP1/TAZ. An increasing body of evidence supports the mechanisms of YAP1/TAZ nucleocytoplasmic shuttling. In a stiff cultured environment, the nucleus encounters mechanical forces and becomes flattened; in addition, the nuclear pores are stretched, subsequently creating conditions for nuclear import of YAP1 ([@B23]). A nuclear localization sequence (NLS) and nuclear export sequence (NES) were identified within TAZ, which contributes to the nucleocytoplasmic distribution of TAZ in different ways: TEAD binding interaction partly conceals the NES; RhoA enhances NLS-induced nuclear import; and TEAD and 14-3-3 competitively bind with TAZ ([@B52]).

Collectively, PTMs can alter YAP1/TAZ stability and/or YAP1/TAZ conformation to change its affinity for other proteins; these eventually mediate YAP1/TAZ subcellular location and content. PTMs mediate YAP1/TAZ through interdependent, synergistic, or competitive mechanisms. A growing body of evidence has revealed the underlying mechanisms of PTMs and YAP1/TAZ activity; however, several important nuances are yet to be elucidated.

Hippo--YAP1/TAZ Signaling in Cardiac Development {#S4}
================================================

Cardiogenesis involves events that alter the spatiotemporal and morphological mechanisms. In the gastrulation period, the mesoderm, which emanates from the anterior primitive streak (APS), produces cardiac progenitor cells ([@B106]). Subsequently, cardiac progenitor cells form two different heart fields: the primary heart field gives rise to the left ventricle and left/right atria, while the secondary heart field generates the right ventricle, left/right atria, and the outflow tract ([@B124]). Postnatally, there is a decrease in CM proliferation alongside an increase in hypertrophy which helps attain the physiologic cardiac size. At approximately postnatal Day 4 (P4), myocardial cell numbers peak, and then stop increasing ([@B60]). Myocardial proliferation can be blunted as early as E11.5 with the help of cardiac gene reprogram; this results in abnormal cardiac growth and perinatal lethality ([@B120]).

Role of Hippo--YAP1/TAZ Signaling and Its Proliferation Output in Heart Development {#S4.SS1}
-----------------------------------------------------------------------------------

The Hippo pathway is a highly conserved mechanism for the regulation of heart size and maturation ([@B31]; [@B91]; [@B34]). Its downstream transcriptional factors, YAP1/TAZ, are key regulators of embryonic and neonatal cardiac development, and this has been validated by multiple lines of evidence ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). Mouse embryonic heart with SAV1 CKO (*Nkx2.5^cre^*: *SAV*^f/f^) shows ventricular septal defect and abnormal heart growth, including thickening of ventricular walls, expansion of trabecular and ventricular myocardial layers, and enlargement of ventricular chambers ([@B37]). Similarly, LATS2 and MST1/2 CKO hearts show the same abnormal heart phenotypes ([@B76]; [@B37]). The SAV CKO heart with reduced phosphorylation of YAP1 exhibit enhanced proliferation of CM and unchanged cell size ([@B37]). A WWTR1 (or TAZ) deficiency in zebrafish heart results in arrested CM proliferation, reduced cardiac trabeculation, and immature trabecular bridges ([@B55]). YAP1 knockdown using Tnnt2-Cre in mouse fetal heart causes cardiac hypoplasia with reduced ventricular chamber size, ventricular septal defects, peripheral edema, and pericardial effusion; these embryos cannot survive beyond E16.5 ([@B116]). YAP1 inactivation represses fetal CM proliferation; however, it does not affect the cell size. Consistent with this, YAP1 deletion in the postnatal heart using Tnnt2-Cre does not significantly affect physical cardiac hypertrophy ([@B116]). Thus, the Hippo pathway regulates the normal cardiac structure and size by mediating the cell proliferation activities of YAP1/TAZ in the fetal and postnatal phase.

###### 

Cardiac output of the Hippo--YAP1/TAZ pathway in cell and animal models.

  Gene          Model            Promoter                                Output                                         
  ------------- ---------------- --------------------------------------- ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  YAP1          Mouse            CKO                                     Tnnt2-Cre                                      Cardiac hypoplasia (reduced ventricular chamber size, ventricular septal defects, peripheral edema, and pericardial effusion) ([@B116])
                Mouse            CKO                                     Nfatc1^IRES--Cre/+^                            Less CM proliferation, impaired compact myocardium, and early postnatal lethality ([@B4])
                Mouse            CKO                                     α-MHC-Cre                                      Blunted cardiac hypertrophy and amplified CM apoptosis and fibrosis; cardiac dilatation and dysfunction after TAC ([@B12])
                Mouse            CKO                                     Nkx2.5-cre                                     Lack of healthy myocardial tissue in the left ventricle wall and an enhancing fibrotic infarct zone following MI ([@B122])
                Mouse            CKO                                     α-MHC-Cre                                      Thinned septal and posterior wall, and chamber dilation ([@B18]).
                Mouse            CKO                                     α-MHC-Cre                                      Increasing CM apoptosis, fibrosis, enlarging infarct size, and impairing cardiac function ([@B18])
                Mouse            Overexpression                          Adeno-associated virus subtype 9: human YAP1   Alleviating MI injury and ameliorating cardiac function ([@B66])
                Mouse            YAP5SA (active YAP1) overexpression     αMyHC-Cre-ERT2                                 Re-entering the cell cycle and reprogramming into more primitive and fetal cell states; thickened ventricular walls and smaller chambers ([@B80])
                Mouse            YAPS112A (active YAP1) overexpression   α-MHC                                          Increased myocardial tissue and reduced LV fibrosis in neonatal heart ([@B122])
                AC16 human CMs   Overexpression                          Lentiviral vectors                             Reducing CM apoptosis, cell hypertrophy, and ROS generation after IR ([@B48])
  WWTR1 (TAZ)   Zebrafish        CKO                                     CRISPR/CAS9                                    CM proliferation arrest, reduced cardiac trabeculation, and immature trabecular bridges ([@B55])
  WW45          Mouse            CKO                                     Myh6-Cre                                       Sustained YAP1 activation in CMs with cell-cycle re-entry, increased de-differentiation, and decreased apoptosis; cardiac dysfunction, severe heart failure, and enhanced mortality in response to TAC ([@B43], [@B44])
  SAV1          Mouse            CKO                                     Nkx2.5-cre                                     Ventricular septal defect and abnormal heart growth (thickening of ventricular walls, expansion of trabecular and ventricular myocardial layers, and enlargement of ventricular chambers) ([@B37])
                Mouse            CKO                                     Myh6^CreERT2^ αMHC-mcm                         Presenting renewal capacity: increase in cell number and myocardial regeneration following cardiac apex resection in postnatal hearts; increased LV CMs, less fibrosis, and improved cardiac function after MI in adult heart ([@B36]; [@B57])
  RASSF1A       Mouse            cardiomyocyte-specific KO               α-MHC-Cre                                      Basal nondistinctive cardiac phenotype or functional abnormality; reduced apoptosis, fibrosis, and hypertrophy after TAC ([@B17])
                Mouse            KO                                      NS                                             Increased hypertrophic response, reduced cardiomyocytes apoptosis, and increased fibrosis after TAC ([@B17])
  MST1/2        Mouse            CKO                                     Nkx2.5-cre                                     Ventricular septal defect and abnormal heart growth ([@B37])
  MST1          Mouse            DN-MST1 overexpression                  CMV-Cre                                        Reducing the size of MI in the area at risk, and decreasing CM apoptosis ([@B85])
                Mouse            DN-MST1 overexpression                  α-MHC                                          Reduced left ventricular remodeling, improved left ventricular function, and enhanced survival rate after MI ([@B73])
  LATS2         Mouse            LATS2 overexpression                    α-MHC                                          Reduced left ventricular systolic and diastolic dysfunction, and smaller left/right ventricle ([@B76])
                Mouse            DN-LATS2 overexpression                 α-MHC                                          Reduced CM apoptosis and enhanced biventricular hypertrophy following TAC ([@B76])
                Mouse            CKO                                     Nkx2.5-cre                                     Ventricular septal defect and abnormal heart growth ([@B37])
  LATS1/2       Mouse            LATS1/2 CKO; YAP1/TAZ CKO               Wt^CreERT2^ allele                             Successful survival past E15.5 without defects in coronary vasculature ([@B121])
                Mouse            CKO                                     Wt^CreERT2^ allele                             Failing to survive past E15.5; smaller hearts with less compacted myocardium ([@B121])
                Mouse            CKO                                     Myh6^CreERT2^                                  Presenting renewal capacity: increasing cell number and regenerating the myocardium following cardiac apex resection in postnatal hearts; increased LV CMs, less fibrosis, and improved cardiac function after MI in adult heart ([@B36])
                Zebrafish        DKO                                     Myh6; Myl7                                     Enhanced Hand2 expression and CM differentiation ([@B101]; [@B26])

NS, not specified, where the specific promotors have not been validated; YAP1, Yes-associated protein 1; TAZ, PDZ-binding motif; CKO, cardiac knockout; KO, knockout; DN, dominant negative, MI, myocardial infarction; CM, cardiomyocytes; TAC, transverse aortic constriction; IR, ischemia--reperfusion; ROS, reactive oxygen species.

###### 

Target genes and cardiac output of the Hippo--YAP1/TAZ pathway.

  Target genes         Type of Regulation   Outcome
  -------------------- -------------------- --------------------------------------------------------------------------------------------------------------------------------------
  *Bmp2b*              Promotion            Activating the BMP pathway to enhance the number of CPCs in the secondary heart field ([@B26])
  *Cyr61* and *CTGF*   Promotion            Promoting CM proliferation ([@B5]; [@B98]; [@B138])
  *Dpp4* and *Dhrs3*   Promotion            Inhibiting subepicardial cells from differentiating into cardiac fibroblasts, thus inducing coronary vessel defects ([@B121])
  *hand2*              Promotion            Regulating differentiation of LPM cells that develop into the atrium of the heart ([@B26])
  *miR-152*            Promotion            Promoting CM proliferation ([@B119])
  *miR-206*            Promotion            Promoting cell hypertrophy and cell survival by downregulating FoxP1 after TAC ([@B126])
  *Nrg1*               Promotion            Activating Nrg1/ErbB2 signaling and reducing CM proliferation, to impair compact myocardium development ([@B4]).
  *Oct-3/4*            Promotion            Maintaining mouse and human embryonic stem cell self-renewal ([@B107])
  *OSM*                Promotion            Regulating CM de-differentiation ([@B43])
  *Park2*              Promotion            Promoting the clearance of impaired mitochondria through autophagy, subsequently enhancing CM resistance to stress ([@B54]; [@B57]).
  *Pik3cb*             Promotion            Activating PI3K-AKT signaling to trigger CM proliferation and survival ([@B123]; [@B67])
  *Sox17*              Inhibition           Disrupting CM differentiation ([@B41])

CM, cardiomyocytes; PI3K, phosphoinositol 3-kinase; TAC, transverse aortic constriction; LPM, lateral-plate mesoderm, CPC, cardiac precursor cell.

Yes-associated protein 1/TAZ, as vital effectors of the Hippo pathway, mainly affect target genes transcription and downstream signaling to exhibit their pro-proliferation activities in heart development ([Table 3](#T3){ref-type="table"}). Neuregulin 1 (Nrg1), secreted by endocardial cells, is a crucial factor in myocardial growth; it induces CM proliferation and re-entry of differentiated CMs in the cell-cycle via Nrg1/ErbB2 signaling ([@B9]; [@B28]). Targeting at *Nrg1*, YAP1/TAZ activates Nrg1/ErbB2 signaling in the endocardium; in addition, loss of YAP1 in the endocardium contributes to less CM proliferation, impaired development of compact myocardium, and early postnatal mortality ([@B4]). Moreover, Nrg1/ErbB4 signaling can reduce the phosphorylation of YAP1 Ser127, and promote YAP1-dependent *CTGF* transcription through the production of the ErbB4--YAP1--TEAD complex in breast cancer cells ([@B33]). Thus, it is hypothesized that YAP1 proliferatively increases output not only by directly mediating *CTGF* transcription, but also indirectly by activating Nrg1/ErbB4 signaling. However, it is unclear whether Nrg1/ErbB4 signaling-dependent YAP1 activation exists in the endocardium.

Through differential gene expression analysis, *Pik3cb* \[which encodes a catalytic subunit of phosphoinositol-3-kinase (PI3K)\] has been identified as the target gene of YAP1. YAP1 promotes *Pik3cb* transcription to activate PI3K-AKT signaling and trigger CM proliferation and survival ([@B123]; [@B67]). In cases with Pik3cb deficiency, the mouse embryo cannot survive beyond E10.5 ([@B10]). Moreover, PI3K-AKT signaling inhibits glycogen synthase kinase 3β (GSK3β)-dependent phosphorylation of β-catenin; the consequent activation of β-catenin promotes CM proliferation ([@B123]). The interaction between the Hippo pathway, Wnt/β-catenin signaling, and PI3K-AKT signaling facilitates the proliferation of CMs. Besides the aforementioned signaling, YAP1/TAZ can also affect bone morphogenetic protein (BMP) pathway to regulate CM proliferation. By upregulating *Bmp2b* transcription, YAP1/TAZ activate the BMP pathway to enhance the number of cardiac precursor cells (CPCs) in the secondary cardiac field ([@B26]). More importantly, BMP2 induces EMT in cardiac cushion, which facilitates the development of valves and septa ([@B30]). These mechanisms delineate the crosstalk between YAP1/TAZ and BMP pathway in cardiac development. Collectively, the above-mentioned findings suggest that the pro-proliferation activities of YAP1/TAZ participate in cardiac development from the fetal to postnatal periods, including the trabeculation and formation of the ventricles and endocardium. Thus, the functions of the Hippo pathway and YAP1/TAZ are shown to be highly conserved, as is the crosstalk between the Hippo pathway and other signaling pathways in cardiac development.

Role of Hippo--YAP1/TAZ Signaling and Its Differentiation Output in Heart Development {#S4.SS2}
-------------------------------------------------------------------------------------

Besides cell proliferation, cardiogenesis involves cell differentiation; in addition, different cell types are involved in salient events during cardiac development. YAP1/TAZ are the key inhibitors of hESC differentiation into cardiac mesoderm. The CKO of LATS1/2 expression in the epicardium by using Wt^CreERT2^ prevents embryos from surviving past E15.5 ([@B121]). Due to the deletion of LATS1/2, activated YAP1 inhibits the differentiation of subepicardial cells into cardiac fibroblasts which induces coronary vascular defects; however, the LATS1/2 CKO and YAP1/TAZ CKO embryos do not exhibit defects of the coronary vasculature. This indicates that LATS1/2 plays an important role in restricting YAP1/TAZ activities and that YAP1/TAZ are essential for normal heart growth ([@B121]). In LATS1/2 CKO heart, downstream genes *Dpp4* and *Dhrs3* transcription is upregulated through the YAP1-TEAD complex, which regulates the differentiation events of subepicardial cells and the coronary vessel remodeling, respectively ([@B121]). Dehydrogenase/reductase superfamily 3 (Dhrs3), a negative modulator of retinoic acid generation, inhibits retinoic acid signaling, which inhibits the differentiation of cardiac fibroblasts ([@B11]; [@B121]). In response to LATS1/2 deficiency, Dipeptidyl peptidase-4 (Dpp4; a serine protease) alters the composition of the ECM and is involved in abnormal vessel development, such as increasing blood islands and defects of mean lacunarity ([@B29]; [@B121]).

Furthermore, YAP1/TAZ regulate the transcription of other target genes to affect the progression of cell differentiation in cardiogenesis, such as *Sox17* and *hand2*. *Sox17*, a member of *SOX* genes, plays a critical role in cardiac development. YAP1 selectively represses the expression of APS cell genes *Sox17* to disrupt the differentiation of CMs ([@B41]). Inhibition of YAP1 by dasatinib induces the differentiation of hESCs into APS-derived endoderm and cardiac mesoderm. In addition to cardiac mesoderm, Sox17 is also required for the development of endocardium. Sox17 deficiency leads to abnormal endocardium with impaired ventricular trabeculation and thickened myocardium ([@B56]). YAP1/TAZ, through facilitation of *hand2* transcription, can regulate the differentiation of the lateral-plate mesoderm (LPM) cells, which finally develop into the atrium of the heart ([@B26]). Hand2 can facilitate CM differentiation, and the expression of hand2 can be potentiated by LATS1/2 double KO (DKO) ([@B101]; [@B26]). Therefore, YAP1/TAZ can facilitate de-differentiation and differentiation activity in different cell types during various phases of cardiac development.

Regulation of YAP1/TAZ by Diverse Mechanisms in Heart Development {#S4.SS3}
-----------------------------------------------------------------

During cardiac development, the content and activity of YAP1/TAZ are not always in a stable level. At approximately P4, myocardial cell numbers peak and this increase is reconciled with the percentage of nuclear YAP1 ([@B60]). During the late maturation of trabeculae, CMs need to withdraw from the cell cycle and differentiate; if not, non-compaction cardiomyopathy occurs. YAP1 may modulate these events ([@B38]). These studies indicate that during the early stage of development, there are high levels of YAP1/TAZ activity and abundance, contributing to cell proliferation and de-differentiation; however, in the late stage, the proliferation effects of YAP1/TAZ are blunted for normal cardiac development, which underscores the importance of the spatiotemporal modulation of YAP1/TAZ. Thus, YAP1/TAZ activities need to be fine-tuned spatiotemporally depending upon the pace of cardiogenesis.

A diverse range of mechanisms are involved in the precise modulation of YAP1/TAZ activities in cardiac homeostasis and appropriate cardiac size. As noted previously, it is imperative to focus on the PTMs of YAP1/TAZ, as these affect the subcellular localization and activity of YAP1/TAZ. Previous studies have mainly shown that the phosphorylation of YAP1/TAZ is dependent on the canonical Hippo pathway. In the SAV1 CKO heart, YAP1 that is phosphorylated at Ser127 is reduced, thereby causing CM proliferation ([@B37]). Moreover, Nrg1/ErbB4 signaling can inhibit LATS1-dependent phosphorylation at YAP1 Ser127 and promote YAP1-dependent *CTGF* transcription ([@B33]). Cullin-RING ligases (CRLs), also known as the ubiquitin ligases, consist of Cullins, substrate-recognition, and RING proteins that mediate proteolysis of cellular proteins ([@B94]). CRL-dependent ubiquitination appears to play an important role in temporal regulation of the Hippo--YAP1/TAZ signaling during cardiac development. In the developing heart, CRLs trigger the ubiquitination-induced degradation of MST1; this, in turn, induces dephosphorylation and nuclear translocation of YAP1, thereby ensuring CM proliferation ([@B138]). Nonetheless, the ubiquitination effect of CRLs depends on the neddylation of a ubiquitin-like protein, NEDD8. Consequently, cardiac-specific inhibition of NEDD8 attenuates the activity of CRLs and thereafter blunts the cell-proliferation activity of YAP1; this causes ventricular hypoplasia and non-compaction and, eventually, heart failure and neonatal death in mice ([@B138]).

In the developing heart, endogenous microRNAs (miRNAs) regulate the Hippo pathway and YAP1/TAZ to maintain heart homeostasis; miRNAs, small non-coding RNA molecules, silence mRNAs and suppress mRNA translation to control cardiac development ([@B1]; [@B7]). miR302-367 restrains MST1, LATS2, and MOB1b, which reduces the phosphorylation of YAP1 Ser127 and enhances the nuclear translocation of YAP1 ([@B112]). miR302-367, through activation of YAP1, promotes cell proliferation in embryonic and postnatal CMs ([@B112]). Using functional screen and computational approaches, some miRNAs were found to promote YAP1-dependent CM proliferation by targeting and inhibiting the members of Hippo signaling ([@B112]; [@B19]). For example, the predicted targets of miR-520d-3p are TAOK1/2 and LATS2; in addition, members of the miR-17 family repress TAOK1/2/3, MST2, SAV1, LATS2, MOBKL1A, and others ([@B19]). Subsequently, miR-520d-3p, miR-17 family and other detected miRNAs enhance the nuclear localization of YAP1 and induce pro-proliferation activity. However, inactivation of a single miRNA (such as miR-520d-3p or miR-17 family) does not have any obvious effect on YAP1 activity; this suggests that none of these miRNAs can individually maintain YAP1 nuclear location and cell proliferation. This indicates that multiple endogenous miRNAs synergistically, but not individually, regulate Hippo signaling-induced cell proliferation during cardiac development.

In the early postnatal period, cell--cell junctions in CMs progressively mature and modulate nuclear-cytoplasmic localization of YAP1/TAZ. The dystrophin-glycoprotein complex (DGC), a kind of transmembrane complex, serves as a link between the cellular cytoskeletal system and the ECM ([@B103]). DGC directly binds to YAP1 at the cell membrane, suppressing YAP1 activity. This interaction is synergistically augmented by the activation of the Hippo pathway; this suggests that Hippo signaling and DGC work in concert to inhibit the proliferation of murine CM ([@B82]). A cell junction protein Fat4 binds angiomotin-like 1 (AMOTL1, a isoform of angiomotin \[AMOT\] family) with YAP1 at the cell junction, leading to impaired cell proliferation in postnatal mouse heart; this is independent of the canonical Hippo pathway ([@B98]). In the absence of Fat4, YAP1 translocates to the nucleus, promoting YAP1-dependent *CTGF* transcription; this leads to thicker ventricular myocardium and interventricular septum in the mouse heart with increased cell proliferation ([@B5]; [@B98]). Similar to this, AMOTL1 can bind to LATS2 at tight junction, and activate LATS2 to enhance YAP1 phosphorylation and repress YAP1 activity ([@B92]). Therefore, cell junction related proteins may induce cytoplasmic sequestration of YAP1/TAZ; the consequent inhibition of YAP1 activity impairs heart growth after birth. Interestingly, AMOTL1 exhibits a dichotomous effect on the regulation of YAP1 activity. YAP1, forming a complex with AMOTL1, co-translocates to the nucleus and triggers proliferation activity as a result of Fat4 deficiency ([@B98]); in addition, AMOTL1 inhibits YAP1 with the help of other junction proteins or the Hippo pathway ([@B92]).

The above-mentioned studies reveal that the protein level and stability of YAP1/TAZ play a pivotal role in cardiac function and development. YAP1/YAZ imbalance leads to abnormal cardiac development, dysfunction, and even mortality. And YAP1/TAZ are mediated by several complex mechanisms such as PTMs, endogenous miRNAs, and cell--cell junctions, which makes it difficult to understand the complete molecular network and remains to be studied.

Role of Hippo--YAP1/TAZ Signaling in Cardiac Disease {#S5}
====================================================

The heart can be damaged by several stimuli such as inadequate nutrition, oxygen deficiency, and hemodynamic stress. Among these, ischemic heart disease plays a major role in cardiac disease. The regulation of the Hippo--YAP1/TAZ pathway appears to be cardiac protective, with relevant effects on cell proliferation, apoptosis, and cardiac remodeling ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}).

Role of Hippo--YAP1/TAZ Signaling in Cardiac Ischemia-Reperfusion and Myocardial Infarction {#S5.SS1}
-------------------------------------------------------------------------------------------

An increasing body of evidence has implicated YAP1/TAZ in the causation of cardiac ischemia-reperfusion (IR) damage. IR induces activation of MST1 in mouse heart; however, after overexpressing dominant-negative MST1 (DN-MST1), the inactive MST1 induces reduction in myocardial infarction (MI) size in areas at risk of mouse heart ([@B85]). Endogenous MST1 potentiates IR-induced myocardial injury mainly by increasing apoptosis and partly by inhibiting autophagy, which is independent of the canonical Hippo pathway ([@B125]; [@B85]). Mechanistically, the Ras-association domain family 1 isoform A (RASSF1A) enhances MST1 activity and translocation to the mitochondria; thereafter, activated MTS1 augments Bax- or Bcl-xL-induced apoptosis and suppresses Beclin1-mediated autophagy ([@B125]; [@B85]). In this setting, CM autophagy, as a protective mechanism, degrades and recycles harmful cytoplasmic components, which contributes to repair of IR damage and promotes cell survival; in contrast, apoptosis was shown to perform an anti-survival role in IR damage ([@B88]). Similar results have been observed in models of MI. After MI, endogenous MST1 potentiates left ventricular (LV) enlargement, impairs LV ejection fraction, and reduces the survival rate by suppressing autophagy ([@B89]; [@B73]). MI-mediated MST1 activation stabilizes the Beclin1 homodimer, and suppresses the downstream output of Beclin1 to inhibit autophagy; this impairs the recycling of harmful components and protein quality control ([@B73]). Besides the MST1--Bax--Bcl-xL axis, MST1 mediates the canonical Hippo pathway to exert pro-apoptotic activity. In cultured CMs, LATS2 was shown to increase cell apoptosis in a dose-dependent manner; in contrast, dominant-negative LATS2 was found to suppress MST1-induced apoptosis ([@B76]). IR induces activation of NF2 and potentiation of MST1 activity, which increases CM apoptosis; hearts lacking NF2 by Cre^αMHC^ exhibit diminished phosphorylation of MST1 and activation of YAP1 ([@B75]). In the NF2 CKO heart, enhanced YAP1 activity protects against IR damage. Collectively, these findings suggest that MST1 participates in IR and MI injury by enhancing apoptosis and reducing autophagy; moreover, MST1 works as a negative regulator in cardiac protection through Hippo-dependent or -independent mechanisms. Based on the available evidence, it can be indirectly inferred that the Hippo pathway may be an anti-survival mediator in cardiac IR and MI damage.

As mentioned previously, IR and MI stress induce activation of the Hippo pathway and inactivation of YAP1/TAZ. Activated YAP1 has a protective effect on IR-damaged heart. Lentivirus-generated YAP1 overexpression in AC16 human CMs decreases CM apoptosis, cell hypertrophy, and generation of reactive oxygen species (ROS), which protects CMs from IR injury ([@B48]). Interestingly, downregulation of the hypertrophy effect of YAP1 is not consistent with the results of previous studies that showed that YAP1 promotes CM hypertrophy after IR stress ([@B126]; [@B136]). This downregulation of the hypertrophy effect may be secondary to decreased apoptosis and ROS generation instead of direct regulation by YAP1; therefore, there exists a difference. Several mechanisms explain the cardioprotective function of YAP1. YAP1 inhibits the ataxia--telangiectasia mutated (ATM)/ATM-and Rad3-related (ATR) DNA-damage cascade to decrease apoptosis ([@B48]). ATM and ATR are sensors of DNA lesions that recognize failed DNA repairs and excessive DNA lesions and consequently trigger apoptosis ([@B99]). In addition, YAP1 mediates mitochondrial homeostasis to resist ischemic stress. YAP1 can activate optic atrophy 1 (OPA-1)-mediated mitochondrial fusion, which ensures mitochondrial homeostasis ([@B72]). Mitochondrial fusion can reduce IR-induced mitochondrial fragmentation and mitochondrial oxidative stress, and suppress mitochondrial apoptosis; this promotes cell survival and alleviates cardiac IR injury ([@B3]; [@B72]). *Park2* (a YAP1 target gene) encodes Parkin, which is an important E3 ubiquitin ligase in the outer mitochondrial membrane. Parkin promotes the clearance of impaired mitochondria through mitochondrial autophagy, which enhances stress resistance of CMs ([@B54]; [@B57]). Moreover, YAP1 binding to Forkhead box protein O1 (FoxO1) was shown to facilitate antioxidant catalase and manganese superoxide dismutase transcription; the consequent decrease in ROS generation was shown to protect CMs against IR-induced oxidative stress ([@B102]). In the setting of MI, heterozygous inactivation of YAP1 in heart enhances CM apoptosis, fibrosis, enlarges infarct size, and impairs cardiac function; YAP1 activation using adeno-associated virus subtype 9: human YAP1 (AAV9: hYAP1) can alleviate MI injury and ameliorate cardiac function ([@B66]). In contrast to IR, YAP1 exerts anti-apoptosis activity via activation of PI3K-AKT signaling and increases CM proliferation against MI damage. Therefore, YAP1 mainly suppresses cell apoptosis through several downstream pathways and outputs to protect CMs and the heart from IR and MI damage.

Role of Hippo--YAP1/TAZ Signaling in Cardiac Pressure Overload {#S5.SS2}
--------------------------------------------------------------

Similar to IR damage, endogenous RASSF1A phosphorylates and activates MST1 to promote CM apoptosis and impair cardiac function following transverse aortic constriction (TAC) - a form of PO ([@B17]). This RASSF1A-induced apoptosis can be inhibited by MST1 deficiency. In the heart with CM-specific KO of RASSF1A, endogenous MST1 activation is abolished, and there is reduced apoptosis, fibrosis, and hypertrophy after TAC ([@B17]). Thus, the RASSF1A-MST1 pathway is implicated in causing heart damage in response to PO stress. Another component of the Hippo pathway, LATS2, is elevated and activated after TAC. Cardiac overexpression of LATS2 was shown to be associated with diminished left ventricular systolic and diastolic dysfunction and smaller left and right ventricles ([@B76]). Overexpression of dominant negative LATS2 (DN-LATS2) in the murine heart was found to repress CM apoptosis and promote hypertrophy following TAC ([@B76]). In addition, a recent study showed activation of endogenous YAP1 (the terminal effector of the Hippo pathway) in the compensated phase in response to TAC ([@B12]). Heterozygous cardiac-specific YAP1 KO mice, when subjected to TAC, present blunted cardiac hypertrophy and amplified CM apoptosis and fibrosis, with resultant cardiac dilatation and dysfunction ([@B12]). The Hippo pathway, as a deleterious regulator, has been shown to exacerbate PO-induced cardiac damage; therefore, inhibition of the Hippo pathway may have a cardioprotective effect against PO injury. Mechanistically, YAP1 directly triggers the transcription of target genes to mediate downstream output and to protect the heart against PO damage. *miR-206* is identified as the novel target gene of YAP1; thus, YAP1-induced miR-206 expression promotes cell hypertrophy and cell survival by downregulating the expression of the Forkhead box protein P1 (FoxP1) ([@B126]). YAP1, through its regulation of miR-206, promotes cell hypertrophy and exerts a cardioprotective effect in response to TAC. Moreover, YAP1 promotes *Pik3cb* transcription to activate PI3K-AKT signaling and trigger CM proliferation and survival ([@B123]; [@B67]). Collectively, these studies demonstrate the cardioprotective role of YAP1/TAZ against several stressors. Thus, YAP1/TAZ may serve as a therapeutic target in many cardiac diseases.

Pernicious Role of YAP1/TAZ in Cardiac Disease {#S5.SS3}
----------------------------------------------

Although YAP/TAZ undertake the cardioprotective role against cardiac damage, high levels of YAP1/TAZ activity are not always beneficial. The effects of long-term suppression of Hippo signaling or activation of YAP1/TAZ in cardiac disease are opposite to those of short-term suppression. Clinical ischemic heart disease and idiopathic dilated cardiomyopathy (DCM) is characterized by enhanced YAP1/TAZ protein levels and increased transcriptional activity with the resultant upregulation of target genes, such as *ankyrin repeat domain 1*, *CTGF*, and *CYR61*; moreover, this phenomenon was observed in the murine heart with desmin-related cardiomyopathy ([@B40]). The WW45 CKO by Myh6-Cre mice show sustained YAP1 activation in CMs, which induces cardiac dysfunction, severe heart failure, and enhanced mortality in response to TAC ([@B43], [@B44]). CMs are subject to cell-cycle re-entry, increased de-differentiation, and decreased apoptosis; however, heart with active YAP1 cannot be rescued from PO damage ([@B43], [@B44]). This may be explained by the dual role of oncostatin M (OSM), which is identified as a novel target of the YAP1-TEAD1 complex. OSM promotes CM de-differentiation and induces the expression of stem cell markers to improve CM resistance to damage; however, excessive OSM stimulation inhibits CM contractility and induces cardiac remodeling ([@B53]). In addition, YAP1-dependent OSM expression further activates YAP1 by inhibiting LATS2-induced phosphorylation, thereby forming a positive feedback loop ([@B43]). This positive feedback mechanism results in sustained YAP1 activation and redundant OSM, which exacerbates cardiac injury and heart failure upon PO. Furthermore, the YAP1/TEAD1-OSM feedback cycle develops in the heart of high-fat-diet (HFD)-fed mice following PO, and contributes to the progression of diabetic cardiomyopathy ([@B44]).

These observations suggest a pleiotropic role of YAP1 ([@B44]). YAP1 activation during the acute phase of CM injury can induce compensatory cell proliferation and de-differentiation, which temporarily improves the tolerance of CM to damage. In later periods, persistent activation of YAP1 produces cardiac dysfunction and heart failure, which may be partly caused by the YAP1/TEAD1--OSM positive feedback loop and cardiac remodeling. However, these events do not completely explain the cardiac pathology, and there is a need to further explore the underlying mechanisms. The available evidence suggests the significance of sustaining the appropriate YAP1/TAZ protein level in therapy of cardiac disease.

The involvement of the Hippo pathway in cardiac fibrosis and remodeling explains the pernicious role of YAP1/TAZ in cardiac disease. In a murine DCM model, endogenous Angiotensin II (Ang II) was shown to activate YAP1 and promote the proliferation of cardiac fibroblasts and their transdifferentiation to myofibroblasts; subsequently, these changes were found to induce cardiac remodeling and impaired cardiac contractility ([@B45]). The Hippo--YAP1/TAZ pathway, as a mechano-sensor, is affected by mechanical signaling through cell geometry and alterations in cytoskeletal tension; this may help elucidate the pathological mechanism of chronic heart failure ([@B21]). The subcellular localization and activity of YAP1/TAZ varies in cells with different matrix stiffness. In a stiff matrix, there is nuclear translocation and higher transcriptional activity of YAP1/TAZ; in contrast, a soft matrix is characterized by cytoplasmic sequestration and reduced activity of YAP1/TAZ ([@B86]). The above studies potentially support the hypothesis that, in the context of cardiac ECM remodeling and/or fibrosis, the ECM stiffness and/or cytoskeletal tension may change and affect YAP1 activity; furthermore, activated YAP1 modulates the progression of ECM remodeling and fibrosis, which further exacerbates cardiac injury and even contributes to the development of chronic heart failure. However, the relationship between mechanical stimuli, remodeling/fibrosis, and YAP1/TAZ is not well characterized; therefore, studies to identify YAP1/TAZ activity and effects in cardiac disease are urgently needed.

Role of Hippo--YAP1/TAZ Signaling in Cardiac Regeneration {#S6}
=========================================================

Several endogenous and exogenous factors may cause cardiac damage and induce cardiac dysfunction. The heart is a highly differentiated organ with limited regenerative activity; this makes it difficult to restore normal function after any injury ([@B84]). Moreover, the regenerative capability of the adult heart is less than that of the neonatal heart. Consequently, cardiac regeneration can be activated through re-entry of terminally differentiated cells into cell cycle, reactivation of cell proliferation, and/or differentiation of stem cells into CMs, which contributes to post-damage recovery ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}; [@B96]; [@B84]).

As a pathway that controls organ size, Hippo--YAP1/TAZ signaling is essential for cardiac regeneration and could be applied for cardiac regeneration and targeted therapeutics in cardiac disease. The downstream effectors of YAP1/TAZ have clear biological effects in cardiac regeneration and CM protection. Studies have shown that adult and postnatal hearts with the deletion of SAV or LATS1/2 exhibit renewal capacity, which contributes to recovery after MI and cardiac apex resection ([@B36]; [@B57]). Postnatal hearts lacking Hippo exhibit increase in cell number and myocardial regeneration following cardiac apex resection; post-MI, SAV CKO hearts show increased LV CMs, less fibrosis, and improved cardiac function ([@B36]; [@B57]). Mechanically, SAV deletion was found to upregulate cell cycle genes and heart growth-related genes, which increases DNA synthesis and induces cell-cycle re-entry ([@B57]). Among these upregulated genes, *Park2* (encoding Parkin) was found to promote cell regeneration following stress. Parkin participates in the clearance of damaged mitochondria through mitochondria autophagy and apoptosis, and decreases the CM sensitivity to ischemic stress ([@B54]; [@B57]). Additionally, studies have demonstrated enhanced expression of Paired-like homeodomain transcription factor 2 (Pitx2) in the Hippo-deficient heart ([@B111]). Pitx2, as a transcriptional factor, has the capacity to regulate several target genes encoding mitochondrial, oxidation-reduction, and respiratory chain proteins via binding to YAP1 or other undefined co-factors. Therefore, Pitx2 and YAP1 may synergistically trigger anti-oxidative effect and proliferation activity to improve the stress resistance and regeneration of adult and neonatal heart ([@B102]; [@B111]). These findings suggest that the Hippo pathway plays the role of a pernicious mediator in the context of cardiac regeneration.

The YAP1 CKO neonatal heart lacks healthy myocardial tissue in the LV wall and shows enhanced fibrotic infarct zone following an MI; neonatal heart expressing active form of YAP1 exhibits increased myocardial tissue and reduced LV fibrosis ([@B122]). Thus, the proliferative activity of YAP1 is essential for cardiac regeneration, and its regenerative activity is involved in proliferative gene programs. Mechanically, glycolytic YAP1 activation upregulates miR-152 expression to increase CM proliferation in neonatal mice ([@B119]). Furthermore, miR-152 suppresses the expression of cell-cycle inhibitory proteins, such as p27kip and DNA methyltransferase1 (DNMT1), leading to re-entry of neonatal CMs in the cell cycle. YAP1 activation promotes cell proliferation not only directly through targeting of the *CTGF* but also indirectly through inhibition of cell-cycle-inhibitory proteins; this contributes to neonatal cardiac regeneration and repair after MI injury ([@B33]; [@B119]). As mentioned in Section "Role of Hippo--YAP1/TAZ Signaling and Its Differentiation Output in Heart Development," YAP1/TAZ have the capacity to induce proliferation and de-differentiation through targeting of the related genes (*Pik3cb*, *Dpp4*, *Dhrs3*, *SOX17*, *Bmp2b*, and others), which may induce CMs to re-enter the cell cycle and regeneration ([@B11]; [@B49]; [@B67]; [@B24]; [@B26]; [@B41]; [@B121]).

In addition to their action on highly differentiated CMs, YAP1/TAZ regulate stem cells to undergo differentiation and proliferation to achieve cardiac regeneration. P2Y~2~ receptor (P2Y~2~R) is a pro-regenerative GPCR that regulates cell regeneration after damage ([@B115]). Activated P2Y~2~R promotes the proliferation and migration of human c-Kit^+^ cardiac progenitor cells (hCPCs) via activation of YAP1 ([@B47]). Moreover, hCPCs improves cardiac function in MI animal models, which supports the use of hCPCs for stem cell therapy in cardiac failure ([@B22]). YAP5SA, an active version of YAP1, is overexpressed in the mouse heart. YAP5SA overexpression causes CMs to partially re-enter the cell cycle; in addition, CMs can be reprogrammed into a more primitive and fetal cell state, whereby the heart exhibits thickened ventricular walls and smaller chambers ([@B80]). Active Yes phosphorylates YAP1 on one or more tyrosine residues; subsequently, phosphorylated YAP1 translocates into the nucleus and induces the transcription of the key pluripotency factor *Oct-3/4* ([@B107]). Oct-3/4 is critical for maintaining the self-renewal capacity of mouse and human ESCs. It promotes the cell cycle re-entry of ESCs via suppressing the transcription of cyclin-dependent kinase inhibitors ([@B58]). These findings indicate that YAP1 plays a critical role in maintaining the proliferative and de-differentiation capacity of stem cells and promoting adult CM renewal following injury.

Yes-associated protein 1/TAZ have the capacity to reactivate CM proliferation and may play a role in cardiac regeneration and therapy for cardiac disease. Nonetheless, the complete mechanism of action and the effects of YAP1/TAZ in cardiac development and disease remain an enormous puzzle. Therefore, further research is required to unravel the contributory mechanisms in order to clearly understand the therapeutic potential of targeted activation of the YAP1/TAZ signaling pathway in myocardial disease and cardiac regeneration.

Compounds That Regulate Hippo--YAP1/TAZ Signaling {#S7}
=================================================

Several reports have focused on the role of Hippo--YAP1/TAZ signaling in cardiac disease to explore the efficacy of leading therapeutic compounds and agents. The YAP1/TAZ--TEAD complex is considered a novel drug target to affect its biological output. Verteporfin, an inhibitor of YAP1, has been widely used to study the Hippo--YAP1/TAZ pathway ([@B47]; [@B44]). Verteporfin combined with YAP1 prevents the interaction of the YAP1-TEADs complex; verteporfin alters the conformation of YAP1 to enhance its binding with trypsin as well as tryptic cleavage ([@B71]; [@B109]). As mentioned in Section "Role of Hippo--YAP1/TAZ Signaling and Its Differentiation Output in Heart Development," YAP1/TEAD1-OSM feedback cycle exacerbates heart failure and the progression of diabetic cardiomyopathy in HFD-fed mice following TAC ([@B44]). Verteporfin treatment via suppressing YAP1/TEAD1 complex alleviates cardiac dysfunction and improves the survival rate of HFD-fed mice by increasing the expression of CM dedifferentiation protein and by attenuating myocardial infiltration. P2Y~2~R-induced YAP1 activation promotes the proliferation and migration of hCPCs, which can be repressed by verteporfin ([@B47]). Therefore, verteporfin may abolish the capacity of hCPCs in repairing MI injury ([@B22]). YAP1/TAZ luciferase reporter assays have identified apigenin as a potential YAP1 inhibitor; it was found to disrupt the interaction between YAP1 and TEAD ([@B62]). Apigenin, a kind of flavonoid, was found to exhibit a protective effect against cardiovascular diseases. *In vivo* and *vitro*, apigenin suppresses ROS production, loss of mitochondrial membrane potential (MMP), and apoptosis via PI3K/AKT signaling as well as mitochondrial Notch1/Hes1 signaling; this was found to protect H9C2 cells and rat hearts against IR injury ([@B42]; [@B137]). However, there is no evidence to suggest that apigenin can mediate the Hippo--YAP1/TAZ pathway to defend heart against stress.

Yes-associated protein 1/TAZ are affected by other pathways; in addition, certain drugs have been shown to target the upstream regulation of YAP1. Dasatinib, which targets the mitogen-activated protein kinase (MAPK) pathway (a pro-proliferative pathway, in contrast to Hippo signaling), may affect YAP1 phosphorylation and inhibit its activity ([@B100]; [@B35]). Inhibition of YAP1 by dasatinib was found to induce differentiation of hESCs into APS-derived endoderm and cardiac mesoderm, consequently affecting the progression of cell differentiation in cardiogenesis ([@B41]). GPCRs are targeted by extracellular ligands and regulate YAP1 activity. As mentioned in Section "Role of Hippo--YAP1/TAZ Signaling and Its Differentiation Output in Heart Development," Ang II and melatonin activate YAP1 through GPCRs to induce corresponding changes in cardiac function ([@B45]; [@B72]). YAP1 is activated by endogenous Ang II to promote the proliferation of cardiac fibroblasts and their transdifferentiation to myofibroblasts, inducing cardiac remodeling and DCM ([@B45]). In addition, melatonin facilitates OPA-1-mediated mitochondrial fusion via activating YAP1, which attenuates IR-induced mitochondrial apoptosis and alleviates cardiac IR damage ([@B72]). Dobutamine enhances YAP1 Ser127 phosphorylation and cytoplasmic sequestration through β-adrenergic receptor (a class of GPCRs) rather than the Hippo pathway ([@B6]). A35 (an antitumor compound) induces mutation of YAP1 Ser127, which induces the recovery of proliferative inhibition and apoptosis compared to wild-type YAP1 ([@B134]). Although Dobutamine and A35 can mediate YAP activity in cancer cells, their effects on YAP1 in CMs and heart tissue are yet to be elucidated.

In conclusion, drugs and compounds that control kinases upstream and/or downstream of YAP1/TAZ can regulate YAP1/TAZ activity and subsequently influence cardiac injury. Undoubtedly, YAP1/TAZ is a potential therapeutic target for cancer and cardiac disease. However, the latent regulatory network of YAP1/TAZ has not been completely elucidated in previous research, especially in the context of cardiac disease.

Author Contributions {#S8}
====================

NH, XC, and YL participated in research design. NH and JL supervised in research design. XC and YL performed the data analysis. NH, JL, XC, and YL wrote or contributed to the writing of the manuscript.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by the National Natural Science Foundation of China (grant Nos. 81773720, 81402928, and 81573433) and Guangzhou Municipal Science and Technology Project (grant No. 201804010490).

[^1]: Edited by: Mark J. Ranek, Johns Hopkins University, United States

[^2]: Reviewed by: Hyun Woo Park, Yonsei University, South Korea; Dominic Del Re, Rutgers, The State University of New Jersey, United States

[^3]: This article was submitted to Striated Muscle Physiology, a section of the journal Frontiers in Physiology
